Compare ARK Genomic Revolution ETF (ARKG) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Northrop Grumman Corporation — how do they compare? ARK Genomic Revolution ETF trades at $40.69, while Northrop Grumman Corporation trades at $539.15 (market cap $76.65B). The key difference: Northrop Grumman Corporation pays a 1.74% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Northrop Grumman Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | NOC | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $768.02 |
52-Week Low | $23.09 | $496.02 |
Market Cap | — | $76.65B |
Enterprise Value | — | $90.87B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Northrop Grumman (NOC) trades at $539.63, up 1.39% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a $95.61B backlog, 10.8% net margin, and consistent cash flow growth. Analyst consensus remains bullish with a $694.40 price target, though technical indicators show resistance near $542.
NOC presents a compelling value opportunity with reasonable valuation (P/E 16.92) and strong defense sector positioning. Key risks include political budget uncertainty and execution challenges. The upcoming Q2 earnings on July 21, 2026, will be crucial for confirming growth trajectory amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
